-
About US
About US
- Patients
-
Professional Medical Solutions
Professional Medical Solutions
- News
- Investor Relations
AcoArt Orchid® & Dhalia®
Above-the-knee DCBAbove-the-knee DCB
· Lipophilic excipient matrix + paclitaxel, improving drug transfer rate with optimization
· Provide various product specifications from 20 to 300mm, of which Acotec exclusively owns the specification of 300mm, offering optimal treatment for patients with long lesions
Exclusive drug-coating technology
AcoArt drug-coated balloon adopts the stable natural excipient matrix— magnesium stearate as the drug carrier. Moreover, the exclusive paclitaxel coating technique significantly reduced drug shedding while being delivered in the vessel
Data source: Testing results of the third-party laboratory commissioned by Acotec
The complete balloon size distribution optimizes the selection scope
Catheter diameters cover 3mm to 12mm, including the industry-first half-size diameter specification for DCB, with catheter lengths from 20mm to 300mm, far longer than similar products. It not only provides the optimal choice according to the lesion conditions but also improves the health and economic benefits
Enroll complex lesions with an average lesion length of nearly 15cm. The late lumen loss of over half of the CTO patients is only 0.05mm at 6th month in the DCB group, showing superior efficacy
1. Chen Zhong,Guo Wei,Jiang Weiliang et al. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population.[J] .J Endovasc Ther, 2019, 26: 471-478.
2. Rosenfield Kenneth,Jaff Michael R,White Christopher J et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.[J] .N Engl J Med, 2015, 373: 145-53.
3. Presented by Prof. Changwei Liu @ CEC 2018. 4. Presented by Prof. Changwei Liu @ CEC 2019. 5. Presented by Prof. Jian Dong @ CEC 2021.
The late lumen loss is only 0.05mm at 6th month in the DCB group, showing superior efficacy
Data source: Acotec Drug-Coated Balloon Catheter Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial，JACC Cardiovasc Interv. 2016 Sep 26;9(18):1941-9.
The 24-month results show that the patency rate of DCB is much higher than that of PTA
Data source: Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I，JACC Cardiovasc Interv. 2018 Dec 10;11(23):2347-2353.
The 5-year long-term results show that the forward safety of DCB is higher than that of PTA
Data source: Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial，J Vasc Surg. 2021 Sep;74(3):756-762.e3.
| Name | AcoArt Orchid® | AcoArt Dhalia® |
Drug | Paclitaxel | Paclitaxel |
Excipient | Magnesium stearate (lipophilic) | Magnesium stearate (lipophilic) |
Diameter（mm） | 3/3.5/4/4.5/5/5.5/6/7/8/9/10/12 | 2/2.5/3/3.5/4/4.5/5/5.5/6/7/8/9/10/12 |
Length（mm） | 20/30/40/60/80/100/120/150/200/250/300 | 20/30/40/60/80/100/120/150/200/250/300 |
Guidewire（inch） | 0.035 | 0.018 |
Sheath（F） | 5-8 | 4-8 |
NP（Bar） | 6 | 6 |
RBP（Bar） | Max.18 | Max.18 |
Copyright © 2023 先瑞达医疗科技控股有限公司 京ICP备19054161号-2 MINETHINK